Literature DB >> 26044748

Angiotensin-(1-7) is Reduced and Inversely Correlates with Tau Hyperphosphorylation in Animal Models of Alzheimer's Disease.

Teng Jiang1, Ying-Dong Zhang1, Jun-Shan Zhou1, Xi-Chen Zhu2, You-Yong Tian1, Hong-Dong Zhao1, Huan Lu2, Qing Gao1, Lan Tan3, Jin-Tai Yu4,5.   

Abstract

As a recently identified bioactive peptide of brain renin-angiotensin system (RAS), angiotensin-(1-7) [Ang-(1-7)] along with its metabolic enzyme angiotensin-converting enzyme (ACE) 2 and its receptor Mas forms ACE2/Ang-(1-7)/Mas axis. Accumulating evidence suggests an essential role of ACE2/Ang-(1-7)/Mas axis in maintaining normal cognitive functions in both animals and human subjects, and dysregulation of this axis contributed to the pathogenesis of several neurodegenerative diseases such as hypertension-induced neurodegeneration and vascular dementia. To date, whether this axis was associated with the etiology and progression of Alzheimer's disease (AD), the most prevalent neurodegenerative disease in the elderly, remains unclear. In the current study, by using senescence-accelerated mouse prone 8 (SAMP8) mice, an animal model of sporadic AD, we showed for the first time that the level of Ang-(1-7) in the brain was significantly reduced during disease progression. More importantly, an inverse correlation was found between Ang-(1-7) level and tau hyperphosphorylation, a pathological hallmark of AD, in cerebral cortex and hippocampus of SAMP8 mice. Meanwhile, this has been further confirmed in P301S mice, an animal model of pure tauopathy. All these findings suggested that Ang-(1-7), the main effector of brain ACE2/Ang-(1-7)/Mas axis, might be implicated in the etiology and progression of AD, possibly via modulation of tau hyperphosphorylation.

Entities:  

Keywords:  Alzheimer’s disease; Angiotensin-(1-7); Hyperphosphorylation; P301S mice; SAMP8; Tau

Mesh:

Substances:

Year:  2015        PMID: 26044748     DOI: 10.1007/s12035-015-9260-9

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  44 in total

Review 1.  Novel disease-modifying therapies for Alzheimer's disease.

Authors:  Teng Jiang; Jin-Tai Yu; Lan Tan
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Angiotensin-(1-7) improves cognitive function in rats with chronic cerebral hypoperfusion.

Authors:  Wei Xie; Donglin Zhu; Li Ji; Minjie Tian; Chang Xu; Jingping Shi
Journal:  Brain Res       Date:  2014-05-20       Impact factor: 3.252

3.  Suppressing inflammation by inhibiting the NF-κB pathway contributes to the neuroprotective effect of angiotensin-(1-7) in rats with permanent cerebral ischaemia.

Authors:  Teng Jiang; Li Gao; Jun Guo; Jie Lu; Yao Wang; Yingdong Zhang
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 4.  ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good.

Authors:  Ping Xu; Srinivas Sriramula; Eric Lazartigues
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-12-22       Impact factor: 3.619

5.  The expression of angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis are upregulated after acute cerebral ischemic stroke in rats.

Authors:  Jie Lu; Teng Jiang; Liang Wu; Li Gao; Yao Wang; Feng Zhou; Shugang Zhang; Yingdong Zhang
Journal:  Neuropeptides       Date:  2013-09-18       Impact factor: 3.286

6.  Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy.

Authors:  Patrice Delobel; Isabelle Lavenir; Graham Fraser; Esther Ingram; Max Holzer; Bernardino Ghetti; Maria Grazia Spillantini; R Anthony Crowther; Michel Goedert
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

7.  Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study.

Authors:  Sevil Yasar; Jin Xia; Wenliang Yao; Curt D Furberg; Qian-Li Xue; Carla I Mercado; Annette L Fitzpatrick; Linda P Fried; Claudia H Kawas; Kaycee M Sink; Jeff D Williamson; Steven T DeKosky; Michelle C Carlson
Journal:  Neurology       Date:  2013-08-02       Impact factor: 9.910

8.  Conversion of Aβ43 to Aβ40 by the successive action of angiotensin-converting enzyme 2 and angiotensin-converting enzyme.

Authors:  Shuyu Liu; Junjun Liu; Yukie Miura; Chiaki Tanabe; Tomoji Maeda; Yasuo Terayama; Anthony J Turner; Kun Zou; Hiroto Komano
Journal:  J Neurosci Res       Date:  2014-05-14       Impact factor: 4.164

9.  ACE2-Ang-(1-7)-Mas Axis in Brain: A Potential Target for Prevention and Treatment of Ischemic Stroke.

Authors:  Teng Jiang; Li Gao; Jie Lu; Ying-Dong Zhang
Journal:  Curr Neuropharmacol       Date:  2013-03       Impact factor: 7.363

Review 10.  A Role for the Brain RAS in Alzheimer's and Parkinson's Diseases.

Authors:  John W Wright; Leen H Kawas; Joseph W Harding
Journal:  Front Endocrinol (Lausanne)       Date:  2013-10-25       Impact factor: 5.555

View more
  27 in total

Review 1.  Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22.

Authors:  Sadashiva S Karnik; Khuraijam Dhanachandra Singh; Kalyan Tirupula; Hamiyet Unal
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

Review 2.  Brain angiotensin II and angiotensin IV receptors as potential Alzheimer's disease therapeutic targets.

Authors:  Jessika Royea; Edith Hamel
Journal:  Geroscience       Date:  2020-07-22       Impact factor: 7.713

3.  Angiotensin (1-7) delivered orally via probiotic, but not subcutaneously, benefits the gut-brain axis in older rats.

Authors:  Thomas W Buford; Yi Sun; Lisa M Roberts; Anisha Banerjee; Sujitha Peramsetty; Anthony Knighton; Amrisha Verma; Drake Morgan; Gonzalo E Torres; Qiuhong Li; Christy S Carter
Journal:  Geroscience       Date:  2020-05-26       Impact factor: 7.713

4.  Probiotic Releasing Angiotensin (1-7) in a Drosophila Model of Alzheimer's Disease Produces Sex-Specific Effects on Cognitive Function.

Authors:  C Aaron Smith; Haddon Smith; Lisa Roberts; Lori Coward; Gregory Gorman; Amrisha Verma; Qiuhong Li; Thomas W Buford; Christy S Carter; Patricia Jumbo-Lucioni
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

5.  Resilience of Alzheimer's Disease to COVID-19.

Authors:  Jingwen Li; Xi Long; Heqing Huang; Jine Tang; Chunli Zhu; Shaoping Hu; Jing Wu; Jinghong Li; Zhicheng Lin; Nian Xiong
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

6.  Neurofibrillary Tangles and Conversion to Mild Cognitive Impairment with Certain Antihypertensives.

Authors:  Whitney Wharton; Liping Zhao; Kyle Steenland; Felicia C Goldstein; Julie A Schneider; Lisa L Barnes; Marla Gearing; Sevil Yasar
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

7.  Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial.

Authors:  Whitney Wharton; Felicia C Goldstein; Malú G Tansey; Alexandra L Brown; Sonum D Tharwani; Danielle D Verble; Amarallys Cintron; Patrick G Kehoe
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

8.  Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid-β and tau pathology.

Authors:  Patrick Gavin Kehoe; Steffenny Wong; Noura Al Mulhim; Laura Elyse Palmer; J Scott Miners
Journal:  Alzheimers Res Ther       Date:  2016-11-25       Impact factor: 6.982

9.  Electroacupuncture Reduces Aβ Production and BACE1 Expression in SAMP8 Mice.

Authors:  Wei-Guo Dong; Feng Wang; Ye Chen; Xue-Hua Zheng; Yong-Cai Xie; Wan-Qing Guo; Hong Shi
Journal:  Front Aging Neurosci       Date:  2015-07-29       Impact factor: 5.750

10.  Brain Formaldehyde is Related to Water Intake behavior.

Authors:  Ting Li; Tao Su; Yingge He; Jihui Lu; Weichuan Mo; Yan Wei; Rongqiao He
Journal:  Aging Dis       Date:  2016-10-01       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.